Head to Head Analysis: Atrion (ATRI) vs. Align Technology (ALGN)
Atrion (NASDAQ: ATRI) and Align Technology (NASDAQ:ALGN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.
Atrion pays an annual dividend of $4.80 per share and has a dividend yield of 0.8%. Align Technology does not pay a dividend. Atrion pays out 26.6% of its earnings in the form of a dividend. Align Technology has increased its dividend for 15 consecutive years.
This table compares Atrion and Align Technology’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional and Insider Ownership
59.0% of Atrion shares are owned by institutional investors. Comparatively, 82.9% of Align Technology shares are owned by institutional investors. 23.1% of Atrion shares are owned by company insiders. Comparatively, 1.6% of Align Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Atrion and Align Technology’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Atrion||$143.49 million||7.79||$27.58 million||$18.05||33.46|
|Align Technology||$1.08 billion||18.67||$189.68 million||$3.29||76.43|
Align Technology has higher revenue and earnings than Atrion. Atrion is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Atrion has a beta of 0.85, suggesting that its share price is 15% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Atrion and Align Technology, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Align Technology has a consensus target price of $237.64, suggesting a potential downside of 5.49%. Given Align Technology’s higher possible upside, analysts plainly believe Align Technology is more favorable than Atrion.
Align Technology beats Atrion on 12 of the 16 factors compared between the two stocks.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety. It has developed a range of valves designed to fill, hold and release controlled amounts of fluids or gasses on demand for use in various intubation, intravenous, catheter and other applications in areas, such as anesthesia and oncology. Its cardiovascular product, MPS2 Myocardial Protection System (MPS2), is the system used in open-heart surgery that delivers fluids and medications, mixes critical drugs and controls temperature, pressure and other variables. The Company manufactures specialized medical devices that disinfect contact lenses. Its other medical and non-medical product lines consist of instrumentation and associated disposables.
Align Technology Company Profile
Align Technology, Inc. designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment. The Clear Aligner segment consists of its Invisalign System, which includes Invisalign Full, Teen and Assist (Comprehensive Products), Express/Lite (Non-Comprehensive Products) and Vivera Retainers, along with its training and ancillary products for treating malocclusion (Non-Case). The Scanner segment consists of intra-oral scanning systems and other services available with the intra-oral scanners that provide digital alternatives to the traditional cast models. The Scanner segment includes its iTero scanner and OrthoCAD services.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.